OKYO Pharma insider reports 10.5M-share holding

OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone has filed an initial ownership report on Form 3.

Accepted by SEC EDGAR 03/18/2026 - 08:35 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone has filed an initial ownership report on Form 3. The filing shows that he directly holds 10,526,416 shares of common stock of OKYO Pharma Ltd following the reported position, establishing his status as a significant shareholder.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider CERRONE GABRIELE M

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Holding	COMMON STOCK	--	--	--

Holdings: COMMON STOCK — 10,526,416 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the OKYO Form 3 filed by Gabriele M. Cerrone show?

The Form 3 shows that director and ten percent owner Gabriele M. Cerrone directly holds 10,526,416 shares of OKYO Pharma Ltd common stock, establishing his initial reported ownership position with the company.

Is Gabriele M. Cerrone a major shareholder of OKYO Pharma Ltd (OKYO)?

Yes. The Form 3 identifies Gabriele M. Cerrone as both a director and a ten percent owner of OKYO Pharma Ltd, with a reported direct holding of 10,526,416 common shares.

Does the OKYO Form 3 report any recent insider buying or selling?

No transactions are reported. The Form 3 is an initial statement of beneficial ownership that lists Gabriele M. Cerrone’s direct holding of 10,526,416 OKYO common shares without showing any new purchases or sales.

What type of security is reported in the OKYO Form 3 for Gabriele M. Cerrone?

The Form 3 reports ownership of common stock of OKYO Pharma Ltd. It lists a direct holding of 10,526,416 common shares following the reported position, with no derivative securities shown.

How is ownership characterized in the OKYO Form 3 for Gabriele M. Cerrone?

The filing characterizes the position as direct ownership of OKYO Pharma Ltd common stock. It shows a total of 10,526,416 shares held directly, with no indirect or derivative holdings disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

CERRONE GABRIELE M

(Last) (First) (Middle)

C/O OKYO PHARMA LTD,

14-15 CONDUIT STREET

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK	10,526,416	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Gabriele Cerrone	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)